Lead Product(s) : NM26-2198
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Kaken Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.
Product Name : NM26-2198
Product Type : Antibody
Upfront Cash : Undisclosed
January 13, 2021
Lead Product(s) : NM26-2198
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Kaken Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement